Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Major histocompatibility complex (MHC) class I downregulation is the primary immune evasion mechanism associated with failure in anti-PD-1/PD-L1 blockade therapies for cancer. Here, we examined the role of MEK signaling pathway inhibition in head and neck squamous cell carcinoma (HNSCC) both in vitro and in vivo. We found that trametinib, a small molecule inhibitor of MEK, significantly enhanced MHC class I and PD-L1 expression in human HNSCC cell lines, and this occurred via STAT3 activation. Trametinib also further upregulated the increase in CXCL9 and CXCL10 expression caused by IFN-γ in HNSCC cells, which is associated with T cell infiltration in tumor tissues. Finally, we evaluated the therapeutic efficacy of trametinib combined with an anti-PD-L1 monoclonal antibody in vivo, using SCCVII mouse syngeneic tumor model for HNSCC. While neither PD-L1 blockade nor trametinib treatment alone affected tumor growth, the combined therapy significantly delayed tumor growth. Our results indicate that in the combined therapy trametinib increases CD8+ T cell infiltration in the tumor site and upregulates antigen presentation, and this may be associated with enhanced PD-L1 blockade efficacy. Furthermore, our results suggest that this combination would therapeutically benefit patients with HNSCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“improved antigen presentation on MHC class I molecules (Dushyanthen et al., 2017; Kang et al., 2019; Liu et al., 2015)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Kang et al., 2019
Experimental — accuracy not yet measuredIn the citing paper
“secretion of TH1 cytokines such as CXCL9 and CXCL10 (Kang et al., 2019)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Kang et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101 · cited 2×
“To override the suppression of anti-tumor immune response, immune checkpoint inhibitors (ICIs) have been developed to target the PD-1/PD-L1 pathway that have shown remarkable and durable therapeutic efficacy in HNSCC.(4,5) However, only approximately 15–20% of patients respond to this treatment strategy.”
BackgroundComprehensive genomic characterization of head and neck squamous cell carcinomas
The Cancer Genome Atlas Network (2015) · Nature · doi:10.1038/nature14129 · Cited by 3,877
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804 · cited 1×
“It is noteworthy that STAT3 is involved in the upregulation of MHC class I expression, because many signals involved in immune suppression and tumor promotion are associated with STAT3 activation.(40,41) Based on the presence of effectors (CD8 T cells) and suppressors (PD-L1 cells), tumor microenvironments can be clas…”
BackgroundClassifying Cancers Based on T-cell Infiltration and PD-L1
Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,411 · cited 1×
“Based on the presence of effectors (CD8 T cells) and suppressors (PD-L1 cells), tumor microenvironments can be classified into four categories.(42,43) Using this classification system, type II (TILPD-L1) and III (TILPD-L1) tumors are predicted to respond poorly to anti-PD-1/PD-L1 mAb therapy.”
BackgroundLee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., Niu, G., Kay, H., Mulé, J., Kerr, W. G., et al. (2005) · Nature Medicine · doi:10.1038/nm1325 · Cited by 1,031 · cited 1×
“It is noteworthy that STAT3 is involved in the upregulation of MHC class I expression, because many signals involved in immune suppression and tumor promotion are associated with STAT3 activation.(40,41) Based on the presence of effectors (CD8 T cells) and suppressors (PD-L1 cells), tumor microenvironments can be clas…”
BackgroundLugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953 · cited 1×
“Therefore, additional therapies are needed that can be used in combination with ICIs to increase their efficacy and response rate.(6) Several anticancer agents have been shown to modulate the immune system via off-target effects, suppressing tumor growth by enhancing anti-tumor immunity in the preclinical stages.”
BackgroundFrederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944 · cited 1×
“Meanwhile, PDL1 expression appears to be variably associated with the MAPK pathway, depending on the experimental context; specifically, MAPK pathway inhibitors can up- or down-regulate PD-L1 expression in tumor cells.(11,17,23) Given that studies have been done almost in melanoma which have frequent BRAF mutations, c…”
BackgroundChow, L. Q. M., Haddad, R., Gupta, S., Mahipal, A., Mehra, R., Tahara, M., Berger, R., Eder, J. P., Burtness, B., Lee, S.-H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1478 · Cited by 857 · cited 2×
“To override the suppression of anti-tumor immune response, immune checkpoint inhibitors (ICIs) have been developed to target the PD-1/PD-L1 pathway that have shown remarkable and durable therapeutic efficacy in HNSCC.(4,5) However, only approximately 15–20% of patients respond to this treatment strategy.”
BackgroundSelf-citation
Cited by
Cancer immunotherapy: Pros, cons and beyond
Tan, S., Li, D., & Zhu, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109821 · Cited by 688
Nucleotide metabolism: a pan-cancer metabolic dependency
Mullen, N. J., & Singh, P. K. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00557-7 · Cited by 466
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion
Jiang, Y., & Zhan, H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.013 · Cited by 319
The cutting-edge progress of immune-checkpoint blockade in lung cancer
Zhou, F., Qiao, M., & Zhou, C. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00577-5 · Cited by 231
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01899-4 · Cited by 223
“Kang reported that the MEK inhibitor trametinib could block the MAPK pathway and thereby increase the MHC-I, which may lead to improved ICB efficacy [121].”
Background
Metadata
- Authors
- Kang, S.-H., Keam, B., Ahn, Y.-O., Park, H.-R., Kim, M., Kim, T. M., Kim, D.-W., & Heo, D. S.
- Affiliations
- Seoul National University (KR)
- Corresponding author
- Keam, Bhumsuk
- ORCID
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2018-09-21
- Volume
- 8
- Issue
- 1
- Pages
- e1515057-e1515057
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC6287796
- OpenAlex
- W2891878264
- Cited by
- 72
- References
- 45
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 7 · 2023: 10 · 2022: 12 · 2021: 11 · 2020: 16 · 2019: 3
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- OncoImmunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Ministry of Health & Welfare, Republic of Korea (1420140)
- Korea Health Industry Development Institute, Republic of Korea (HI17C2085)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- trametinib, MEK inhibition, PD-L1 inhibitors, head and neck squamous cell carcinoma, MHC class I upregulation, STAT3 signaling, PD-L1 expression, CXCL9, CXCL10, interferon-gamma, CD8+ T cell infiltration, tumor immune evasion, combination immunotherapy, antigen presentation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma. https://app.cochat.ai/papers/10.1080/2162402x.2018.1515057
- The paper
- Kang, S.-H., Keam, B., Ahn, Y.-O., Park, H.-R., Kim, M., Kim, T. M., Kim, D.-W., & Heo, D. S. (2019). Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma. OncoImmunology. https://doi.org/10.1080/2162402x.2018.1515057
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.